摘要
目的:研究依洛尤单抗对进展性脑卒中患者血脂水平、血小板功能及肢体功能的影响。方法:选取2022年4月—2023年4月福建医科大学附属泉州第一医院收治的90例进展性脑卒中患者为研究对象,按照随机数表法将其分对照组(45例,按照常规治疗方案治疗)和观察组(45例,常规治疗+依洛尤单抗治疗)。比较两组治疗前后血脂水平、血小板功能、肢体功能情况及不良反应。结果:治疗前,两组血脂水平比较,差异无统计学意义(P>0.05);治疗后,两组甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇(TC)较治疗前降低,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗前,两组血小板黏附率、血小板聚集率比较,差异无统计学意义(P>0.05);治疗后,两组血小板黏附率、血小板聚集率较治疗前降低,且观察组低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。治疗前,两组Fugl-Meyer运动功能评定量表(FMA)评分及改良Barthel指数比较,差异无统计学意义(P>0.05);治疗后,两组FMA评分及改良Barthel指数较治疗前提升,且观察组高于对照组,差异有统计学意义(P<0.05)。结论:进展性脑卒中患者治疗过程中在常规治疗基础上加用依洛尤单抗进行治疗,可以有效改善患者血脂水平,提升血小板功能,促进患者肢体功能恢复。
Objective:To investigate the effect of Evolocumab on blood lipid levels,platelet function and limb function in patients with progressive stroke.Method:A total of 90 patients with progressive stroke admitted to Quanzhou First Hospital Affiliated to Fujian Medical University from April 2022 to April 2023 were selected as the study objects,and were divided into control group(45 cases,treated according to conventional treatment)and observation group(45 cases,treated with conventional treatment+Evolocumab)according to random number table method.Blood lipid levels,platelet function,limb function before and after treatment and adverse reactions were compared between the two groups.Result:Before treatment,there were no significant differences in blood lipid levels between the two groups(P>0.05);after treatment,triglyceride(TG),low-density lipoprotein cholesterol(LDL-C)and total cholesterol(TC)in two groups were lower than those before treatment,and the observation group were lower than the control group,the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in the platelet adhesion rate and platelet agglutination rate between the two groups(P>0.05);after treatment,the platelet adhesion rate and platelet agglutination rate of the two groups were lower than those before treatment,and the observation group were lower than the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Before treatment,there were no significant differences in Fugl-Meyer motor function rating scale(FMA)score and modified Barthel index between the two groups(P>0.05);after treatment,the FMA score and modified Barthel index of the two groups were higher than those before treatment,and the observation group were higher than the control group,the differences were statistically significant(P<0.05).Conclusion:In the treatment of patients with progressive stroke,choosing Evolocumab on the basis of conventional treatment can more effectively improve their blood lipid levels,enhance platelet function,and promote the recovery of limb function.
作者
周玉云
王惠民
洪全龙
ZHOU Yuyun;WANG Huimin;HONG Quanlong(Quanzhou First Hospital Affiliated to Fujian Medical University,Quanzhou 362000,China;不详)
出处
《中外医学研究》
2024年第3期17-21,共5页
CHINESE AND FOREIGN MEDICAL RESEARCH